17 medicines will not be guaranteed supply (with list)

Pharmaceutical Network September 25th, September 23rd, the whole pharmaceutical network issued "on the publicity of the Shenzhen Group procurement catalog (first batch) 2019 transaction results can not guarantee the supply of drugs notice."
notice showed that 17 of the 2019 results of the Shenzhen Group's procurement catalogue (the first batch) were not guaranteed to supply.
notice will be made public from 23 September to 25 September 2020 at 17:00 and will be dealt with accordingly after the publicity period expires.
treatment measures are as follows: 1. No justification for not supplying, and do not agree to the "ten, deal rules, (1) transaction rules" in accordance with the "ten, transaction rules" for the price adjustment of the transaction drugs, after the publicity period will be disqualified.
2. For drugs that cannot be supplied before the date of the signing of the 2019 tri-party contract for the sale of medicines in medical institutions (September 1, 2020), the deadline is for the delivery of the drugs to the designated place of receipt of the drug network by September 30, 2020.
if the contract fails to be served without a valid reason, it will be disqualified from trading.
. All pharmaceutical and production enterprises that are disqualified from the transaction will bear the corresponding liability for failure of trust.
shenzhen trading platform will be in accordance with the "ten, transaction rules, (2) alternate rules" to start the alternate procedures.
, if the 17 drugs published are disqualified in accordance with the treatment measures, they are subject to the corresponding liability for failure of trust.
from the point of view of not being able to guarantee the supply of drugs, there are low-cost drugs, emergency medicine, children's medicine, these categories are also in recent years the provinces actively scrap the standard directory of regular customers.
of the provincial withdrawal notice, many drugs due to production line transformation, rising costs, raw material shortages, production stoppages and other reasons to submit withdrawal applications.
, the cost problem is a hard injury facing pharmaceutical companies.
, many pharmaceutical production of raw materials, environmental protection, labor and other costs are increasing year by year, but many drugs are still using the price of more than a decade ago, more or even lower prices.
industry insiders say that in recent years, with the rise in production costs to drug companies to bring a lot of pressure.
, tenders need to be reduced.
, on the other hand, for some raw materials cost too high, inevitable losses of cheap drugs, enterprises are not willing to produce, or even forced to stop production.
this situation, the need for pharmaceutical companies to guarantee supply has become a major pain point.
, active scrapping is less of a penalty for pharmaceutical companies than it is for not being able to guarantee supply.
In accordance with the requirements of many provinces, if not normal supply, according to the provisions of light then scrap the bid, cancel the winning bid qualification, deduct the performance bond, heavy into the bad record, cancel all products of the enterprise in the province's winning qualification, or even be kicked out of the provincial market for two years.
how to balance drug profits, drug prices and supply security is the future of the relevant departments and pharmaceutical companies need to further consider.
attached: